CN108884135B - 治疗方法以及可用于其中的药剂 - Google Patents

治疗方法以及可用于其中的药剂 Download PDF

Info

Publication number
CN108884135B
CN108884135B CN201680074679.6A CN201680074679A CN108884135B CN 108884135 B CN108884135 B CN 108884135B CN 201680074679 A CN201680074679 A CN 201680074679A CN 108884135 B CN108884135 B CN 108884135B
Authority
CN
China
Prior art keywords
epha4
amino acid
disease
human
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680074679.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN108884135A (zh
Inventor
P·巴特莱特
A·博伊德
M·盖罗梅塔
L·库珀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
QIMR Berghofer Medical Research Institute
Original Assignee
University of Queensland UQ
Queensland Institute of Medical Research QIMR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015904387A external-priority patent/AU2015904387A0/en
Application filed by University of Queensland UQ, Queensland Institute of Medical Research QIMR filed Critical University of Queensland UQ
Publication of CN108884135A publication Critical patent/CN108884135A/zh
Application granted granted Critical
Publication of CN108884135B publication Critical patent/CN108884135B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201680074679.6A 2015-10-27 2016-10-27 治疗方法以及可用于其中的药剂 Active CN108884135B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015904387A AU2015904387A0 (en) 2015-10-27 A method of treatment and agents useful for same
AU2015904387 2015-10-27
PCT/AU2016/051010 WO2017070738A1 (en) 2015-10-27 2016-10-27 A method of treatment and agents useful for same

Publications (2)

Publication Number Publication Date
CN108884135A CN108884135A (zh) 2018-11-23
CN108884135B true CN108884135B (zh) 2024-03-26

Family

ID=58629613

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680074679.6A Active CN108884135B (zh) 2015-10-27 2016-10-27 治疗方法以及可用于其中的药剂

Country Status (7)

Country Link
US (1) US10617738B2 (enExample)
EP (1) EP3368551B1 (enExample)
JP (1) JP6877419B2 (enExample)
CN (1) CN108884135B (enExample)
AU (1) AU2016345063B2 (enExample)
ES (1) ES2959601T3 (enExample)
WO (1) WO2017070738A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110702916B (zh) * 2019-04-15 2022-06-21 四川大学华西医院 一种整合蛋白质组和糖蛋白组的定量分析方法
EP4308149A4 (en) * 2021-03-18 2025-02-26 Valery Krasnoperov Use of sephb4-hsa fusion protein as a first-line therapy in cancer treatment
AU2022388189A1 (en) * 2021-11-11 2024-05-02 Eisai R&D Management Co., Ltd. Anti-epha4 antibody
WO2023154948A1 (en) * 2022-02-14 2023-08-17 Vasgene Therapeutics Inc. Ephrin type-b receptor 4 (ephb4) agents and production thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2260864A1 (en) * 2009-06-10 2010-12-15 University of Melbourne Therapeutic applications

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
EP0425731B1 (de) 1989-11-03 1994-01-19 Siemens Aktiengesellschaft Controller-Bussystem für einen programmierbaren, flexiblen Digitalsignal-Multiplexer
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
SG47470A1 (en) 1991-04-25 1998-04-17 Univ Brown Res Found Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
DE69423522T2 (de) 1993-04-27 2000-09-21 Cytotherapeutics, Inc. Membran aus einem acrylnitrilpolymer
NZ269041A (en) 1993-06-23 1998-02-26 Univ Brown Res Found Implantable encapsulation device having a cell-tight dry seal at an opening thereof
SG48813A1 (en) 1993-08-12 1998-05-18 Cytotherapeutics Inc Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US5550050A (en) 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5853717A (en) 1994-07-20 1998-12-29 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
US5834029A (en) 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
CA2202747A1 (en) 1995-06-01 1996-12-05 Dennis Keen Warren Communication system to provide called party location and pre-call warning
IN181898B (enExample) 1995-06-07 1998-10-24 Cytotherapeutics Inc
WO1997012635A1 (en) 1995-10-02 1997-04-10 Cytotherapeutics, Inc. Method for treating amyotrophic lateral sclerosis
AUPP674898A0 (en) * 1998-10-27 1998-11-19 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment
JP2007525203A (ja) * 2004-02-27 2007-09-06 オンコセラピー・サイエンス株式会社 ＰＲＣおよびＰＤＡＣａの治療標的としてのＥｐｈＡ４
US20080003210A1 (en) 2006-03-13 2008-01-03 Medimmune, Inc. Non-human primate receptor tyrosine kinases
WO2008150010A1 (ja) * 2007-06-08 2008-12-11 Eisai R & D Management Co., Ltd. γ-セクレターゼの新規基質EphA4を利用したスクリーニング方法
EP2223999B1 (en) * 2007-11-30 2017-10-18 Eisai R&D Management Co., Ltd. Epha4 polypeptide having novel activity and use thereof
EP2653552B1 (en) * 2010-12-17 2016-10-19 Eisai R&D Management Co., Ltd. SCREENING METHOD USING GELATINASE-MEDIATED EphA4 CLEAVAGE REACTION AS AN INDICATOR
MY199344A (en) 2013-02-18 2023-10-24 Vegenics Pty Ltd Ligand binding molecules and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2260864A1 (en) * 2009-06-10 2010-12-15 University of Melbourne Therapeutic applications

Also Published As

Publication number Publication date
US20180339020A1 (en) 2018-11-29
AU2016345063A2 (en) 2018-07-19
WO2017070738A1 (en) 2017-05-04
EP3368551A1 (en) 2018-09-05
EP3368551B1 (en) 2023-07-12
JP6877419B2 (ja) 2021-05-26
ES2959601T3 (es) 2024-02-27
US10617738B2 (en) 2020-04-14
CA3003294A1 (en) 2017-05-04
CN108884135A (zh) 2018-11-23
AU2016345063B2 (en) 2021-08-05
JP2019501112A (ja) 2019-01-17
AU2016345063A1 (en) 2018-05-17
EP3368551A4 (en) 2019-06-05

Similar Documents

Publication Publication Date Title
US10287336B2 (en) Feline erythropoietin receptor agonists
AU2004233985A1 (en) Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof
EP3368551B1 (en) A modified epha4 polypeptide
KR20080021595A (ko) 에리트로포이에틴 변이체
KR20240028341A (ko) 융합 폴리펩티드
EP3366770A1 (en) Dna vaccine against amyloid-beta and tau
CA3003294C (en) Modified epha4 and uses thereof
AU2022325383B2 (en) GPC3-TARGETED ANTIBODY INTERFERON α FUSION PROTEIN AND USE THEREOF
KR102917499B1 (ko) 백혈병 억제 인자 활성을 억제하기 위한 가용성 폴리펩타이드 및 이의 사용 방법
KR102485892B1 (ko) 고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
CN116139278B (zh) 一种tim-3棕榈酰化修饰及靶向多肽在肿瘤免疫治疗中的应用
US20250250320A1 (en) Thrombopoietin receptor fragments and uses thereof
US6872703B2 (en) Insulin receptor-related receptor binding protein
WO2024123702A1 (en) Soluble angiotensin-converting enzyme 2 (ace2) proteins and ace2 fusion proteins
JP2026514409A (ja) ＩｄｅＳバリアントタンパク質及びそれを使用する方法
CN115490770A (zh) 一种能与人eta和人cd3结合的双特异性抗体及其应用
CN117642422A (zh) 用于降低抗体-脂肪酶结合的结构
EP1386965A1 (en) Novel potential-dependent cation channel protein
JP2005287418A (ja) 細胞殺傷性と細胞死防御性とを併せもつペプチド
HK1165461A (en) In tumours differentially expressed gene products and use of the same
HK1165462A (en) In tumours differentially expressed gene products and use of the same
WO2002096944A2 (en) New heterotetrameric potassium channels and uses thereof
ZA200508434B (en) Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof
HK1165468A (en) In tumours differentially expressed gene products and use of the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant